Hims Peptides Launch & Wall Street Revenue Friction Analyzer

Interactive Telehealth Scenario Modeling Workbench vs Analyst Consensus

Reuters Context: Peptide Ramp Friction

Breakeven Month Month 5 Net Profit Positive

Q4 Realized Revenue $38.4M Consensus Target: $45.0M

Wall St Consensus Variance -$6.6M CAUTIOUS GAP

24-Mo Gross Contribution $184.2M 72% Gross Margin

Scenario Presets

Operational Controls

Monthly New Subscribers 15,000

Monthly Sub Price ($) $199

Fulfillment Delay (Weeks) 4 Wks

Regulatory Ramp Lag (Months) 3 Mos

Gross Margin (%) 72%

Blended CAC per Patient ($) $220

Wall St Q4 Estimate ($M) $45.0M

24-Month Revenue Realization vs Analyst Trajectory

Scenario: Operational friction yields $6.6M gap vs consensus.

Unit Economics Breakdown (Month 12 Baseline)

Quarterly Financial Summary

Quarter	Subscribers	Realized Rev	Consensus	Gap